Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist

Multiple Sclerosis

Volumn 10, Issue 3, 2004, Pages 330-331

  van Oosten, B W ^a   Killestein, J ^a   Mathus Vliegen, E M H ^b   Polman, C H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Appetite depressants; Cannabinoid receptor antagonist; Endogenous cannabinoids; Multiple sclerosis; Obesity

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT;

ADULT; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DEMYELINATION; DRUG WITHDRAWAL; FEMALE; HUMAN; LABORATORY TEST; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOGENESIS; SEROLOGY; THORACIC SPINAL CORD; WHITE MATTER;

APPETITE DEPRESSANTS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID;

EID: 3042637406     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1044oa     Document Type: Article

References (9)

1. Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-407.
2. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-26.
3. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413: 527-31.
4. Klein TW, Newton C, Friedman H. Cannabinoid receptors and immunity. Immunol Today 1998; 19: 373-81.
5. McDonald WI, Compston A, Edan G, Goodkin D, Hartung H-P, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-27.
6. Pryce G, Ahmed Z, Hankey DJR, Jackson SJ, Croxford JL, Pocock JM et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003; 126: 2191-202.
7. Vastag B. Experimental drugs take aim at obesity. JAMA 2003; 289: 1763-64.
8. The Association of the British Pharmaceutical Industry, Target Schizophrenia. Accessed on-line 4 February, 2004, at: http://www.abpi.org.uk/publications/publication_details/ targetschizophrenia-2003/section5.asp
9. National Institutes of Health, ClinicalTrials.gov. Accessed on-line 4 February, 2004, at: http://clinicaltrials.gov/ct/show/NCT00075205?order = 1